세계의 비인간 영장류용 바이러스 벡터 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Viral Vectors for Non-human Primates Market - Scope of Report

TMR's report on the global viral vectors for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors for non-human primates market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the viral vectors for non-human primates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors for non-human primates market.

The report delves into the competitive landscape of the global viral vectors for non-human primates market. Key players operating in the global viral vectors for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors for non-human primates Market Report:

• What is the sales/revenue generated by viral vectors for non-human primates across all regions during the forecast period?
• What are the opportunities in the global viral vectors for non-human primates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Viral Vectors for Non-human Primates Market - Research Objectives and Research Approach

The comprehensive report on the global viral vectors for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors for non-human primates market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Viral Vectors for Non-human Primates Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Recent Advancements in Viral Vector Technology
• 5.2. Porter's Five Forces Analysis
• 5.3. List of Leading CROs Offering Non-human Primate based Preclinical Testing Services
• 5.4. PESTLE Analysis
• 5.5. Key Industry Events (Product Approvals, Partnerships, and Collaborations)

6. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Vector Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Vector Type, 2020-2034
  • 6.3.1. Adenoviral Vectors
  • 6.3.2. Adeno-associated Vectors
  • 6.3.3. Retroviral Vectors
  • 6.3.4. Lentiviral Vectors
  • 6.3.5. Others
• 6.4. Market Attractiveness By Vector Type

7. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primates

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 7.3.1. Marmosets
  • 7.3.2. Rhesus macaques
  • 7.3.3. Cynomolgus monkey
  • 7.3.4. Others
• 7.4. Market Attractiveness By Type of Non-human Primates

8. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Application

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Application, 2020-2034
  • 8.3.1. Gene Therapy
  • 8.3.2. Vaccine Research
• 8.4. Market Attractiveness By Application

9. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Therapeutic Area

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Therapeutic Area, 2020-2034
  • 9.3.1. Genetic Disorders
  • 9.3.2. Infectious Diseases
  • 9.3.3. Oncological Disorders
  • 9.3.4. Others
• 9.4. Market Attractiveness By Therapeutic Area

10. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By End-user, 2020-2034
  • 10.3.1. Pharmaceutical and Biotechnology Companies
  • 10.3.2. Academic and Research Institutions
• 10.4. Market Attractiveness By End-user

11. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Region

• 11.1. Key Findings
• 11.2. Market Value Forecast By Region
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness By Region

12. North America Viral Vectors for Non-human Primates Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Vector Type, 2020-2034
  • 12.2.1. Adenoviral Vectors
  • 12.2.2. Adeno-associated Vectors
  • 12.2.3. Retroviral Vectors
  • 12.2.4. Lentiviral Vectors
  • 12.2.5. Others
• 12.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 12.3.1. Marmosets
  • 12.3.2. Rhesus macaques
  • 12.3.3. Cynomolgus monkey
  • 12.3.4. Others
• 12.4. Market Value Forecast By Application, 2020-2034
  • 12.4.1. Gene Therapy
  • 12.4.2. Vaccine Research
• 12.5. Market Value Forecast By Therapeutic Area, 2020-2034
  • 12.5.1. Genetic Disorders
  • 12.5.2. Infectious Diseases
  • 12.5.3. Oncological Disorders
  • 12.5.4. Others
• 12.6. Market Value Forecast By End-user, 2020-2034
  • 12.6.1. Pharmaceutical and Biotechnology Companies
  • 12.6.2. Academic and Research Institutions
• 12.7. Market Value Forecast By Country, 2020-2034
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Vector Type
  • 12.8.2. By Type of Non-human Primates
  • 12.8.3. By Application
  • 12.8.4. By Therapeutic Area
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Viral Vectors for Non-human Primates Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Vector Type, 2020-2034
  • 13.2.1. Adenoviral Vectors
  • 13.2.2. Adeno-associated Vectors
  • 13.2.3. Retroviral Vectors
  • 13.2.4. Lentiviral Vectors
  • 13.2.5. Others
• 13.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 13.3.1. Marmosets
  • 13.3.2. Rhesus macaques
  • 13.3.3. Cynomolgus monkey
  • 13.3.4. Others
• 13.4. Market Value Forecast By Application, 2020-2034
  • 13.4.1. Gene Therapy
  • 13.4.2. Vaccine Research
• 13.5. Market Value Forecast By Therapeutic Area, 2020-2034
  • 13.5.1. Genetic Disorders
  • 13.5.2. Infectious Diseases
  • 13.5.3. Oncological Disorders
  • 13.5.4. Others
• 13.6. Market Value Forecast By End-user, 2020-2034
  • 13.6.1. Pharmaceutical and Biotechnology Companies
  • 13.6.2. Academic and Research Institutions
• 13.7. Market Value Forecast By Country, 2020-2034
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Spain
  • 13.7.5. Italy
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Vector Type
  • 13.8.2. By Type of Non-human Primates
  • 13.8.3. By Application
  • 13.8.4. By Therapeutic Area
  • 13.8.5. By End-user
  • 13.8.6. By Country

14. Asia Pacific Viral Vectors for Non-human Primates Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Vector Type, 2020-2034
  • 14.2.1. Adenoviral Vectors
  • 14.2.2. Adeno-associated Vectors
  • 14.2.3. Retroviral Vectors
  • 14.2.4. Lentiviral Vectors
  • 14.2.5. Others
• 14.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 14.3.1. Marmosets
  • 14.3.2. Rhesus macaques
  • 14.3.3. Cynomolgus monkey
  • 14.3.4. Others
• 14.4. Market Value Forecast By Application, 2020-2034
  • 14.4.1. Gene Therapy
  • 14.4.2. Vaccine Research
• 14.5. Market Value Forecast By Therapeutic Area, 2020-2034
  • 14.5.1. Genetic Disorders
  • 14.5.2. Infectious Diseases
  • 14.5.3. Oncological Disorders
  • 14.5.4. Others
• 14.6. Market Value Forecast By End-user, 2020-2034
  • 14.6.1. Pharmaceutical and Biotechnology Companies
  • 14.6.2. Academic and Research Institutions
• 14.7. Market Value Forecast By Country, 2020-2034
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Vector Type
  • 14.8.2. By Type of Non-human Primates
  • 14.8.3. By Application
  • 14.8.4. By Therapeutic Area
  • 14.8.5. By End-user
  • 14.8.6. By Country

15. Latin America Viral Vectors for Non-human Primates Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Vector Type, 2020-2034
  • 15.2.1. Adenoviral Vectors
  • 15.2.2. Adeno-associated Vectors
  • 15.2.3. Retroviral Vectors
  • 15.2.4. Lentiviral Vectors
  • 15.2.5. Others
• 15.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 15.3.1. Marmosets
  • 15.3.2. Rhesus macaques
  • 15.3.3. Cynomolgus monkey
  • 15.3.4. Others
• 15.4. Market Value Forecast By Application, 2020-2034
  • 15.4.1. Gene Therapy
  • 15.4.2. Vaccine Research
• 15.5. Market Value Forecast By Therapeutic Area, 2020-2034
  • 15.5.1. Genetic Disorders
  • 15.5.2. Infectious Diseases
  • 15.5.3. Oncological Disorders
  • 15.5.4. Others
• 15.6. Market Value Forecast By End-user, 2020-2034
  • 15.6.1. Pharmaceutical and Biotechnology Companies
  • 15.6.2. Academic and Research Institutions
• 15.7. Market Value Forecast By Country, 2020-2034
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Vector Type
  • 15.8.2. By Type of Non-human Primates
  • 15.8.3. By Application
  • 15.8.4. By Therapeutic Area
  • 15.8.5. By End-user
  • 15.8.6. By Country

16. Middle East & Africa Viral Vectors for Non-human Primates Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Vector Type, 2020-2034
  • 16.2.1. Adenoviral Vectors
  • 16.2.2. Adeno-associated Vectors
  • 16.2.3. Retroviral Vectors
  • 16.2.4. Lentiviral Vectors
  • 16.2.5. Others
• 16.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
  • 16.3.1. Marmosets
  • 16.3.2. Rhesus macaques
  • 16.3.3. Cynomolgus monkey
  • 16.3.4. Others
• 16.4. Market Value Forecast By Application, 2020-2034
  • 16.4.1. Gene Therapy
  • 16.4.2. Vaccine Research
• 16.5. Market Value Forecast By Therapeutic Area, 2020-2034
  • 16.5.1. Genetic Disorders
  • 16.5.2. Infectious Diseases
  • 16.5.3. Oncological Disorders
  • 16.5.4. Others
• 16.6. Market Value Forecast By End-user, 2020-2034
  • 16.6.1. Pharmaceutical and Biotechnology Companies
  • 16.6.2. Academic and Research Institutions
• 16.7. Market Value Forecast By Country, 2020-2034
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Vector Type
  • 16.8.2. By Type of Non-human Primates
  • 16.8.3. By Application
  • 16.8.4. By Therapeutic Area
  • 16.8.5. By End-user
  • 16.8.6. By Country

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis By Company (2023)
• 17.3. Market Footprint Analysis
  • 17.3.1. By Region
  • 17.3.2. By Vector Type
• 17.4. Competitive Snapshot
• 17.5. Company Profiles
  • 17.5.1. Lonza
    • 17.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.1.2. Product Portfolio
    • 17.5.1.3. Financial Overview
    • 17.5.1.4. SWOT Analysis
    • 17.5.1.5. Strategic Overview
  • 17.5.2. Thermo Fisher Scientific Inc
    • 17.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.2.2. Product Portfolio
    • 17.5.2.3. Financial Overview
    • 17.5.2.4. SWOT Analysis
    • 17.5.2.5. Strategic Overview
  • 17.5.3. Revvity
    • 17.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.3.2. Product Portfolio
    • 17.5.3.3. Financial Overview
    • 17.5.3.4. SWOT Analysis
    • 17.5.3.5. Strategic Overview
  • 17.5.4. VectorBuilder Inc.
    • 17.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.4.2. Product Portfolio
    • 17.5.4.3. Financial Overview
    • 17.5.4.4. SWOT Analysis
    • 17.5.4.5. Strategic Overview
  • 17.5.5. Creative Biolabs
    • 17.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.5.2. Product Portfolio
    • 17.5.5.3. Financial Overview
    • 17.5.5.4. SWOT Analysis
    • 17.5.5.5. Strategic Overview
  • 17.5.6. Takara Bio Inc
    • 17.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.6.2. Product Portfolio
    • 17.5.6.3. Financial Overview
    • 17.5.6.4. SWOT Analysis
    • 17.5.6.5. Strategic Overview
  • 17.5.7. MERCK KGaA
    • 17.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.7.2. Product Portfolio
    • 17.5.7.3. Financial Overview
    • 17.5.7.4. SWOT Analysis
    • 17.5.7.5. Strategic Overview
  • 17.5.8. Andelyn Biosciences
    • 17.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.8.2. Product Portfolio
    • 17.5.8.3. Financial Overview
    • 17.5.8.4. SWOT Analysis
    • 17.5.8.5. Strategic Overview
  • 17.5.9. Biovian Oy
    • 17.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.9.2. Product Portfolio
    • 17.5.9.3. Financial Overview
    • 17.5.9.4. SWOT Analysis
    • 17.5.9.5. Strategic Overview
  • 17.5.10. Genezen
    • 17.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.5.10.2. Product Portfolio
    • 17.5.10.3. Financial Overview
    • 17.5.10.4. SWOT Analysis
    • 17.5.10.5. Strategic Overview